In particular, in NSCLC carrying mutant KRAS cells are sensitive to glucose deprivation or treatment with metformin, an inhibitor of mitochondrial complex I and of pancreatic cancer cell respiration [58]. The gene discussed is KRAS; the disease is pancreatic neoplasm.